All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Oral SERDs, PROTACs Could Add to Expanding ER+ Advanced Breast Cancer Arsenal

September 12th 2024

Komal Jhaveri, MD, FACP, discusses the emergence of oral SERDs and PROTACs in the treatment of estrogen receptor–positive advanced breast cancer.

Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer

September 11th 2024

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

Clinical Development of Gamma-Delta T-Cell Therapy INB-400 Paused in Glioblastoma

September 11th 2024

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer

September 11th 2024

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

Dr Hiltermann on ARTEMIDE-01 Data With Rilvegostomig in Metastatic NSCLC

September 11th 2024

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

September 11th 2024

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC

September 11th 2024

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

September 11th 2024

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

September 11th 2024

The FDA has granted orphan drug designation to the novel GSK-3β inhibitor elraglusib for the treatment of patients with soft tissue sarcoma.

Study From Researchers at Fox Chase Cancer Center and Johns Hopkins Kimmel Cancer Center Shows Aged Male Fibroblasts Increase Melanoma Treatment Resistance

September 11th 2024

Changes that occur with age in male skin fibroblasts resulted in an increase in the spread of melanoma cells, according to new research from Fox Chase.

Markman Peels Back the Curtain on the Effects of Growing Uncertainties in Gynecologic Oncology

September 11th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Timing of Immunotherapy Administration Is a Key Question to be Answered in Lung Cancer

September 11th 2024

Luis Raez, MD, highlights considerations with phases of treatment in lung cancer, detailing factors affecting use of adjuvant therapy when a patient has a complete response.

TakeAim Lymphoma Tests Proof of Concept for Dual IRAK4/FLT3 Blockade in B-Cell Malignancy Treatment

September 11th 2024

Targeting IRAK4 with emavusertib could be a viable treatment option that offers needed blood-brain barrier penetration in PCNSL.

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial

September 11th 2024

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure

September 10th 2024

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

September 10th 2024

Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.

Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC

September 10th 2024

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC

September 10th 2024

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

September 10th 2024

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

September 10th 2024

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.